RNS Number : 5372D
Animalcare Group PLC
20 October 2022




("Animalcare" or the "Company")




20 October 2022. Animalcare Group plc (AIM: ANCR), the international animal health business, notes that the Interim Results for the six months ended 30 June 2022 ("H1 2022") published by the Company on 27 September 2022 incorrectly stated the following for H1 2022:

·    "Investment in Joint Ventures" should have stated £1,430,000 as at 30 June 2022 (versus £78,000 as published on 27 September 2022);

·    "Total Non-Current Assets" should have stated £85,434,000 as at 30 June 2022 (versus £84,082,000);

·    "Total assets" should have stated £117,886,000 as at 30 June 2022 (versus £116,534,000); and

·    "Net assets" should have stated £80,154,000 as at 30 June 2022 (versus £78,802,000).


Other than the items listed above, all the financial information contained in the Interim Results announcement published by the Company on 27 September 2022 remains accurate.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.




Animalcare Group plc

Chris Brewster, Chief Financial Officer
and Company Secretary

+44 (0)1904 487 687

Stifel Nicolaus Europe Limited

(Nominated Adviser & Joint Broker)

Ben Maddison

Nicholas Harland

Nick Adams


+44 (0)20 7710 7600

 Panmure Gordon

(Joint Broker)

Corporate Finance:

Freddy Crossley/Emma Earl

Corporate Broking:

Rupert Dearden


 +44 (0)20 7886 2500


About Animalcare

Animalcare Group plc is a UK AIM-listed international development-focused veterinary sales and marketing organisation. Animalcare operates in seven countries and exports to approximately 40 countries in Europe and worldwide. The Group is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition.

For more information about Animalcare, please visit

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.